ABSTRACT
Vaccines have undoubtedly been a medical milestone, preventing immeasurable morbidity and mortality from infectious diseases worldwide. Modern vaccines have tremendously reduced the global impact of numerous infections; they have succeeded in eliminating smallpox completely. However, the nature by which vaccines confer their protection—by stimulation of the immune system—means that in rare cases, adverse often immunologically mediated events may occur following vaccination. Some of the most severe of these involve the nervous system. The author provides an overview of the mechanisms of vaccinology, and describes the various vaccines available for particular neurologic illnesses. Possible neurologic adverse events following vaccinations, and the possible mechanisms of these events, are also discussed. Finally, procedures in place to ensure vaccine safety are reviewed.
KEYWORDS
Vaccines - encephalitis - virus - adverse events
REFERENCES
1
Centers for Disease Control and Prevention (CDC) .
Ten great public health achievements—United States, 1900-1999.
MMWR Morb Mortal Wkly Rep.
1999;
48
(12)
241-243
2 World Health Organization .The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization; 1980
3
Riedel S.
Edward Jenner and the history of smallpox and vaccination.
Proc (Bayl Univ Med Cent).
2005;
18
(1)
21-25
(Bayl Univ Med Cent)
4 Plotkin S A, Orenstein W, Offit P A Eds.. Vaccines. 5th ed. Philadelphia: Saunders; 2008
5
Centers for Disease Control and Prevention .
Recommended immunization schedules for persons aged 0–18 years—United States, 2011.
MMWR Morb Mortal Wkly Rep.
2011;
60
(5)
1-4
6 Advisory Committee for Immunization Practices .ACIP Vaccine Recommendations. Atlanta, GA: Centers for Disease Control and Prevention; 2011
7 WHO Expert Committee on Biological Standardization. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. Geneva: World Health Organization; 2005
8
World Health Organization .
Cholera vaccines: WHO position paper.
Wkly Epidemiol Rec.
2010;
85
(13)
117-128
9
Centers for Disease Control and Prevention. Typhoid immunization.
MMWR Recomm Rep.
1994;
43
(RR-14)
10 Centers for Disease Control and Prevention .Travelers' Health, Vaccination. Atlanta, GA: Centers for Disease Control and Prevention; 2009
11
Paessler S, Weaver S C.
Vaccines for Venezuelan equine encephalitis.
Vaccine.
2009;
27
(Suppl 4)
D80-D85
12 Centers for Disease Control and Prevention. Advisory Committee for Immunization Practices. Updated Tdap Vaccine Recommendations from the ACIP, 2010. Atlanta, GA: Centers for Disease Control and Prevention; 2010
13 Mandell G L, Bennett J E, Dolin R. Principles and Practice of Infectious Disease. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005
14
Dalakas M C, Sever J L, Madden D L et al..
Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies.
Rev Infect Dis.
1984;
6
(Suppl 2)
S562-S567
15
Dalakas M C, Bartfeld H, Kurland L T.
The postpolio syndrome: advances in the pathogenesis and treatment.
Ann N Y Acad Sci.
1995;
753
1-412
16
Nathanson N, Kew O M.
From emergence to eradication: the epidemiology of poliomyelitis deconstructed.
Am J Epidemiol.
2010;
172
(11)
1213-1229
17
Centers for Disease Control and Prevention (CDC) .
Certification of poliomyelitis eradication—the Americas, 1994.
MMWR Morb Mortal Wkly Rep.
1994;
43
(39)
720-722
18
Centers for Disease Control and Prevention (CDC) .
Progress toward interruption of wild poliovirus transmission - worldwide, 2009.
MMWR Morb Mortal Wkly Rep.
2010;
59
(18)
545-550
19
Esteves K.
Safety of oral poliomyelitis vaccine: results of a WHO enquiry.
Bull World Health Organ.
1988;
66
(6)
739-746
20
Prevots D R, Sutter R W, Strebel P M, Weibel R E, Cochi S L.
Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease.
Arch Pediatr Adolesc Med.
1994;
148
(5)
479-485
21
Wunner W H, Briggs D J.
Rabies in the 21 century.
PLoS Negl Trop Dis.
2010;
4
(3)
e591
22
Briggs D J.
World Rabies Day: working together to make rabies history.
Vaccine.
2007;
25
6830-6831
23
Dodet B. Asian Rabies Expert Bureau (AREB) .
An important date in rabies history.
Vaccine.
2007;
25
(52)
8647-8650
24
Culbertson C G, Peck Jr F B, Powell H M.
Duck-embryo rabies vaccine; study of fixed virus vaccine grown in embryonated duck eggs and killed with beta-propiolactone (BPL).
J Am Med Assoc.
1956;
162
(15)
1373-1376
25
Fuenzalida E, Palacios R, Borgono J M.
Antirabies antibody response in man to vaccine made from infected suckling-mouse brains.
Bull World Health Organ.
1964;
30
431-436
26
World Health Organization .
Rabies vaccines. WHO position paper.
Wkly Epidemiol Rec.
2007;
82
(49-50)
425-435
27
Gubler D J.
The global emergence/resurgence of arboviral diseases as public health problems.
Arch Med Res.
2002;
33
(4)
330-342
28
Wang S P.
Japanese encephalitis in Taiwan: a review of recent studies.
Bull World Health Organ.
1964;
30
279-284
29
Parida M, Dash P K, Tripathi N K et al..
Japanese Encephalitis Outbreak, India, 2005.
Emerg Infect Dis.
2006;
12
(9)
1427-1430
30
Richter R W, Shimojyo S.
Neurologic sequelae of Japanese B encephalitis.
Neurology.
1961;
11
553-559
31
Grossberg S, Heyman A, Keehn R J.
Neurologic sequelae of Japanese encephalitis. Report of a cooperative study.
Trans Am Neurol Assoc.
1962;
87
114-117
32
Huy B V, Tu H C, Luan T V, Lindqvist R.
Early mental and neurological sequelae after Japanese B encephalitis.
Southeast Asian J Trop Med Public Health.
1994;
25
(3)
549-553
33
Baruah H C, Biswas D, Patgiri D, Mahanta J.
Clinical outcome and neurological sequelae in serologically confirmed cases of Japanese encephalitis patients in Assam, India.
Indian Pediatr.
2002;
39
(12)
1143-1148
34
Kuttner A G, Ts'un T.
Encephalitis in north China. Results obtained with neutralization tests.
J Clin Invest.
1936;
15
(5)
525-530
35
Wilder-Smith A, Halstead S B.
Japanese encephalitis: update on vaccines and vaccine recommendations.
Curr Opin Infect Dis.
2010;
23
(5)
426-431
36
Centers for Disease Control and Prevention .
Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
1993;
42
(RR-1)
1-15
37
Guess H A, Broughton D D, Melton III L J, Kurland L T.
Population-based studies of varicella complications.
Pediatrics.
1986;
78
(4 Pt 2)
723-727
38
Preblud S R.
Varicella: complications and costs.
Pediatrics.
1986;
78
(4 Pt 2)
728-735
39
Choo P W, Donahue J G, Manson J E, Platt R.
The epidemiology of varicella and its complications.
J Infect Dis.
1995;
172
(3)
706-712
40
Mueller N H, Gilden D H, Cohrs R J, Mahalingam R, Nagel M A.
Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.
Neurol Clin.
2008;
26
(3)
675-697
viii
viii
41
Marin M, Güris D, Chaves S S, Schmid S, Seward J F. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC) .
Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
2007;
56
(RR-4, RR-04)
1-40
42
Marin M, Broder K R, Temte J L, Snider D E, Seward J F. Centers for Disease Control and Prevention (CDC) .
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
2010;
59
(RR-3)
1-12
43
Plotkin S A, Starr S E, Connor K, Morton D.
Zoster in normal children after varicella vaccine.
J Infect Dis.
1989;
159
(5)
1000-1001
44
White C J.
Clinical trials of varicella vaccine in healthy children.
Infect Dis Clin North Am.
1996;
10
(3)
595-608
45
Harpaz R, Ortega-Sanchez I R, Seward J F. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) .
Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
2008;
57
(RR-5)
1-30
quiz CE2-CE4
46
Oxman M N.
Zoster vaccine: current status and future prospects.
Clin Infect Dis.
2010;
51
(2)
197-213
47
Sanford M, Keating G M.
Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Drugs Aging.
2010;
27
(2)
159-176
48
Advisory Committee on Immunization Practices .
Recommended adult immunization schedule: United States, 2011.
Ann Intern Med.
2011;
154
(3)
168-173
49
Hornberger J, Robertus K.
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Ann Intern Med.
2006;
145
(5)
317-325
50
Pellissier J M, Brisson M, Levin M J.
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Vaccine.
2007;
25
(49)
8326-8337
51
Rothberg M B, Virapongse A, Smith K J.
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Clin Infect Dis.
2007;
44
(10)
1280-1288
52
Rosenstein N E, Perkins B A, Stephens D S, Popovic T, Hughes J M.
Meningococcal disease.
N Engl J Med.
2001;
344
(18)
1378-1388
53
Molesworth A M, Thomson M C, Connor S J et al..
Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa.
Trans R Soc Trop Med Hyg.
2002;
96
(3)
242-249
54
Khatami A, Pollard A J.
The epidemiology of meningococcal disease and the impact of vaccines.
Expert Rev Vaccines.
2010;
9
(3)
285-298
55
Rosenstein N E, Perkins B A.
Update on Haemophilus influenzae serotype b and meningococcal vaccines.
Pediatr Clin North Am.
2000;
47
(2)
337-352, vi
vi
56
Cartwright K, Noah N, Peltola H. Meningococcal Disease Advisory Board .
Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.
Vaccine.
2001;
19
(31)
4347-4356
57
Rosenstein N E, Perkins B A, Stephens D S et al..
The changing epidemiology of meningococcal disease in the United States, 1992-1996.
J Infect Dis.
1999;
180
(6)
1894-1901
58
Pollard A J, Levin M.
Vaccines for prevention of meningococcal disease.
Pediatr Infect Dis J.
2000;
19
(4)
333-344, quiz 345
59
Pollard A J, Maiden M C.
Epidemic meningococcal disease in sub-Saharan Africa—towards a sustainable solution?.
Lancet Infect Dis.
2003;
3
(2)
68-70
60
Pollard A J.
Global epidemiology of meningococcal disease and vaccine efficacy.
Pediatr Infect Dis J.
2004;
23
(12, Suppl)
S274-S279
61
Centers for Disease Control and Prevention (CDC) .
Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010.
MMWR Morb Mortal Wkly Rep.
2011;
60
(3)
72-76
62
World Health Organization .
Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.
Wkly Epidemiol Rec.
2002;
77
(40)
331-339
63
Brook I.
Current concepts in the management of Clostridium tetani infection.
Expert Rev Anti Infect Ther.
2008;
6
(3)
327-336
64
Pascual F B, McGinley E L, Zanardi L R, Cortese M M, Murphy T V.
Tetanus surveillance—United States, 1998–2000.
MMWR Surveill Summ.
2003;
52
(3)
1-8
65 Galazka A, Bermingham M, Kurian M, Gasse F. Tetanus. In: Murray C JL, Lopez A D, Mathers C D, eds. The Global Epidemiology of Infectious Diseases. Geneva: World Health Organization; 2004: 151-199
66
Gardner P.
Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults.
Infect Dis Clin North Am.
2001;
15
(1)
143-153
67
Centers for Disease Control and Prevention (CDC) .
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
MMWR Morb Mortal Wkly Rep.
2011;
60
(1)
13-15
68
Kretsinger K, Broder K R, Cortese M M Centers for Disease Control and Prevention et al.
Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
MMWR Recomm Rep.
2006;
55
(RR-17)
1-37
69
Roper M H, Vandelaer J H, Gasse F L.
Maternal and neonatal tetanus.
Lancet.
2007;
370
(9603)
1947-1959
70
Garren H.
A DNA vaccine for multiple sclerosis.
Expert Opin Biol Ther.
2008;
8
(10)
1539-1550
71
Hickey M J, Malone C C, Erickson K L et al..
Cellular and vaccine therapeutic approaches for gliomas.
J Transl Med.
2010;
8
100
72
A vaccine against meningitis in Africa.
Lancet Infect Dis.
2011;
11
(1)
1
73
Biedenbender R, Bevilacqua J, Gregg A M, Watson M, Dayan G.
Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.
J Infect Dis.
2011;
203
(1)
75-84
74
Smith L A.
Botulism and vaccines for its prevention.
Vaccine.
2009;
27
(Suppl 4)
D33-D39
75
Rivers TMSF, Schwentker F F.
Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys.
J Exp Med.
1935;
61
(5)
689-702
76
Vital C, Vital A, Gbikpi-Benissan G et al..
Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases.
J Peripher Nerv Syst.
2002;
7
(3)
163-167
77
Levin M C, Krichavsky M, Berk J et al..
Neuronal molecular mimicry in immune-mediated neurologic disease.
Ann Neurol.
1998;
44
(1)
87-98
78
Kalume F, Lee S M, Morcos Y, Callaway J C, Levin M C.
Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing.
J Neurosci Res.
2004;
77
(1)
82-89
79
Pou M A, Diaz-Torne C, Vidal S et al..
Development of autoimmune diseases after vaccination.
J Clin Rheumatol.
2008;
14
(4)
243-244
80
Orbach H, Agmon-Levin N, Zandman-Goddard G.
Vaccines and autoimmune diseases of the adult.
Discov Med.
2010;
9
(45)
90-97
81 Johnson R Ed.. Postinfectious Demyelinating Disease. Philadelphia, New York: Lippincott-Raven; 1998: 181-211
82
Fenichel G M.
Neurological complications of immunization.
Ann Neurol.
1982;
12
(2)
119-128
83
Miravalle A, Biller J, Schnitzler E, Bonwit A.
Neurological complications following vaccinations.
Neurol Res.
2010;
32
(3)
285-292
84
Piyasirisilp S, Schmeckpeper B J, Chandanayingyong D, Hemachudha T, Griffin D E.
Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis.
Ann Neurol.
1999;
45
(5)
595-600
85
Hemachudha T, Phanuphak P, Johnson R T, Griffin D E, Ratanavongsiri J, Siriprasomsup W.
Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies.
Neurology.
1987;
37
(4)
550-556
86
Hemachudha T, Griffin D E, Giffels J J, Johnson R T, Moser A B, Phanuphak P.
Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination.
N Engl J Med.
1987;
316
(7)
369-374
87
Hemachudha T, Griffin D E, Chen W W, Johnson R T.
Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome.
Neurology.
1988;
38
(3)
375-378
88
Takahashi H, Pool V, Tsai T F, Chen R T. The VAERS Working Group .
Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States.
Vaccine.
2000;
18
(26)
2963-2969
89
Swicowa K, Mostowiec S.
[Neurological complications following smallpox vaccination].
Pediatr Pol.
1964;
39
1207-1211
90
Siegert R.
[Behaviour of vaccinia virus in central nervous system injury caused by vaccine. II. Virological studies in the central nervous system].
Dtsch Med Wochenschr.
1957;
82
(49)
2061-2065
91
Siegert R.
[Behaviour of vaccinia virus in central nervous injury caused by vaccine. I. Virological studies at the inoculation site, in the regional lymph nodes and in the blood].
Dtsch Med Wochenschr.
1957;
82
(48)
2021-2024
92
Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child.
JAMA.
1966;
198
(6)
671-672
93
McMahon A W, Eidex R B, Marfin A A Yellow Fever Working Group et al.
Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.
Vaccine.
2007;
25
(10)
1727-1734
94
Lista F, Faggioni G, Peragallo M S et al..
Molecular analysis of early postvaccine mumps-like disease in Italian military recruits.
JAMA.
2002;
287
(9)
1114-1115
95 Neustadt R E, Fineberg H V. The Swine Flu Affair. Honolulu: University Press of the Pacific; 2005
96
Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al..
Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977.
Am J Epidemiol.
1979;
110
(2)
105-123
97
Breman J G, Hayner N S.
Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977.
Am J Epidemiol.
1984;
119
(6)
880-889
98
Langmuir A D, Bregman D J, Kurland L T, Nathanson N, Victor M.
An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines.
Am J Epidemiol.
1984;
119
(6)
841-879
99
Safranek T J, Lawrence D N, Kurland L T Expert Neurology Group et al.
Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study.
Am J Epidemiol.
1991;
133
(9)
940-951
100
Hurwitz E S, Schonberger L B, Nelson D B, Holman R C.
Guillain-Barré syndrome and the 1978-1979 influenza vaccine.
N Engl J Med.
1981;
304
(26)
1557-1561
101
Kaplan J E, Katona P, Hurwitz E S, Schonberger L B.
Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination.
JAMA.
1982;
248
(6)
698-700
102
Kaplan J E, Schonberger L B, Hurwitz E S, Katona P.
Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system.
Neurology.
1983;
33
(5)
633-637
103
Roscelli J D, Bass J W, Pang L.
Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988.
Am J Epidemiol.
1991;
133
(9)
952-955
104
Chen R T, Kent J, Rhodes P, Simon P, Schonberger L.
Investigation of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990–1991.
Post Mark Surveill.
1992;
6
(1)
5-6
105
Lasky T, Terracciano G J, Magder L et al..
The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.
N Engl J Med.
1998;
339
(25)
1797-1802
106
Haber P, DeStefano F, Angulo F J et al..
Guillain-Barré syndrome following influenza vaccination.
JAMA.
2004;
292
(20)
2478-2481
107
Juurlink D N, Stukel T A, Kwong J et al..
Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.
Arch Intern Med.
2006;
166
(20)
2217-2221
108
Stowe J, Andrews N, Wise L, Miller E.
Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.
Am J Epidemiol.
2009;
169
(3)
382-388
109
Nachamkin I, Shadomy S V, Moran A P et al..
Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.
J Infect Dis.
2008;
198
(2)
226-233
110
Lopez Adaros H, Held J R.
Guillain-Barré syndrome associated with immunization against rabies: epidemiological aspects.
Res Publ Assoc Res Nerv Ment Dis.
1971;
49
178-186
111
Pollard J D, Selby G.
Relapsing neuropathy due to tetanus toxoid. Report of a case.
J Neurol Sci.
1978;
37
(1-2)
113-125
112
Tuttle J, Chen R T, Rantala H, Cherry J D, Rhodes P H, Hadler S.
The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States.
Am J Public Health.
1997;
87
(12)
2045-2048
113
Haber P, Sejvar J, Mikaeloff Y, DeStefano F.
Vaccines and Guillain-Barré syndrome.
Drug Saf.
2009;
32
(4)
309-323
114 Stratton K, Almario D A, McCormick M C. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: Institute of Medicine; 2002
115
Ascherio A, Zhang S M, Hernán M A et al..
Hepatitis B vaccination and the risk of multiple sclerosis.
N Engl J Med.
2001;
344
(5)
327-332
116
Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccines in Multiple Sclerosis Study Group .
Vaccinations and the risk of relapse in multiple sclerosis.
N Engl J Med.
2001;
344
(5)
319-326
117
DeStefano F, Verstraeten T, Chen R T.
Hepatitis B vaccine and risk of multiple sclerosis.
Expert Rev Vaccines.
2002;
1
(4)
461-466
118
Harris C, Lee K.
Acute disseminated encephalomyelitis.
J Neurosci Nurs.
2007;
39
(4)
208-212
119
Wingerchuk D M.
Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues.
Adv Neurol.
2006;
98
303-318
120
Young N P, Weinshenker B G, Lucchinetti C F.
Acute disseminated encephalomyelitis: current understanding and controversies.
Semin Neurol.
2008;
28
(1)
84-94
121
Tenembaum S N.
Disseminated encephalomyelitis in children.
Clin Neurol Neurosurg.
2008;
110
(9)
928-938
122
Murthy S N, Faden H S, Cohen M E, Bakshi R.
Acute disseminated encephalomyelitis in children.
Pediatrics.
2002;
110
(2 Pt 1)
e21
123
Mihai C, Jubelt B.
Post-infectious encephalomyelitis.
Curr Neurol Neurosci Rep.
2005;
5
(6)
440-445
124
Murphy J, Austin J.
Spontaneous infection or vaccination as cause of acute disseminated encephalomyelitis.
Neuroepidemiology.
1985;
4
(3)
138-145
125
Solomon T.
New vaccines for Japanese encephalitis.
Lancet Neurol.
2008;
7
(2)
116-118
126
Moore Z S, Seward J F, Lane J M.
Smallpox.
Lancet.
2006;
367
(9508)
425-435
127
Lane J M, Ruben F L, Neff J M, Millar J D.
Complications of smallpox vaccination, 1968.
N Engl J Med.
1969;
281
(22)
1201-1208
128 De Vries E. Post Vaccinial Perivenous Encephalitis. Amsterdam: Elsevier; 1960
129
Miller D L, Ross E M, Alderslade R, Bellman M H, Rawson N S.
Pertussis immunisation and serious acute neurological illness in children.
Br Med J (Clin Res Ed).
1981;
282
(6276)
1595-1599
130
Miller D C, Wadsworth M J, Ross E M.
Pertussis vaccine and severe acute neurological illnesses. Response to a recent review by members of the NCES team.
Vaccine.
1989;
7
(6)
487-489
131
Safety of pertussis vaccine.
Lancet.
1990;
335
(8690)
655-656
132
Griffin M R, Ray W A, Mortimer E A, Fenichel G M, Schaffner W.
Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine.
JAMA.
1990;
263
(12)
1641-1645
133 Stratton K R, How C J, Johnston R B. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, DC: National Academy Press; 1994
134
Currenti S A.
Understanding and determining the etiology of autism.
Cell Mol Neurobiol.
2010;
30
(2)
161-171
135
Wakefield A J, Murch S H, Anthony A et al..
Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.
Lancet.
1998;
351
(9103)
637-641
136
Farrington C P, Miller E, Taylor B.
MMR and autism: further evidence against a causal association.
Vaccine.
2001;
19
(27)
3632-3635
137
Smeeth L, Hall A J, Fombonne E, Rodrigues L C, Huang X, Smith P G.
A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology.
BMC Public Health.
2001;
1
2
138
Hornig M, Briese T, Buie T et al..
Lack of association between measles virus vaccine and autism with enteropathy: a case-control study.
PLoS ONE.
2008;
3
(9)
e3140
139
Bedford H E, Elliman D A.
MMR vaccine and autism.
BMJ.
2010;
340
c655
140
Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.
Lancet.
2010;
375
(9713)
445
141
American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health .
Thimerosal in vaccines—An interim report to clinicians.
Pediatrics.
1999;
104
(3 Pt 1)
570-574
142
Madsen K M, Lauritsen M B, Pedersen C B et al..
Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.
Pediatrics.
2003;
112
(3 Pt 1)
604-606
143
Stehr-Green P, Tull P, Stellfeld M, Mortenson P B, Simpson D.
Autism and thimerosal-containing vaccines: lack of consistent evidence for an association.
Am J Prev Med.
2003;
25
(2)
101-106
144 Stratton K, Gable A, McCormick M C. Immunization Safety Review: Thimerosal-containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press; 2001
145
Pritchard J, Mukherjee R, Hughes R A.
Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation.
J Neurol Neurosurg Psychiatry.
2002;
73
(3)
348-349
146
Kuitwaard K, van Koningsveld R, Ruts L, Jacobs B C, van Doorn P A.
Recurrent Guillain-Barré syndrome.
J Neurol Neurosurg Psychiatry.
2009;
80
(1)
56-59
147
Rutschmann O T, McCrory D C, Matchar D B. Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines .
Immunization and MS: a summary of published evidence and recommendations.
Neurology.
2002;
59
(12)
1837-1843
148
Fiore A E, Uyeki T M, Broder K Centers for Disease Control and Prevention (CDC) et al.
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
MMWR Recomm Rep.
2010;
59
(RR-8)
1-62
149
Broder K R, Cortese M M, Iskander J K Advisory Committee on Immunization Practices (ACIP) et al.
Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
2006;
55
(RR-3)
1-34
150
Chen R T, Rastogi S C, Mullen J R et al..
The vaccine adverse event reporting system (VAERS).
Vaccine.
1994;
12
(6)
542-550
151
Singleton J A, Lloyd J C, Mootrey G T, Salive M E, Chen R T. VAERS Working Group .
An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system.
Vaccine.
1999;
17
(22)
2908-2917
152
Chen R T, Glasser J W, Rhodes P H The Vaccine Safety Datalink Team et al.
Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States.
Pediatrics.
1997;
99
(6)
765-773
153
Greene S K, Kulldorff M, Lewis E M et al..
Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.
Am J Epidemiol.
2010;
171
(2)
177-188
154
Perkins F T.
Safety of vaccines.
Br Med Bull.
1969;
25
(2)
208-212
155
Bohlke K, Davis R L, Marcy S M Vaccine Safety Datalink Team et al.
Risk of anaphylaxis after vaccination of children and adolescents.
Pediatrics.
2003;
112
(4)
815-820
156
Fisher M C.
Vaccine safety.
Pediatr Infect Dis J.
2008;
27
(9)
827-830
157
Demirjian A, Levy O.
Safety and efficacy of neonatal vaccination.
Eur J Immunol.
2009;
39
(1)
36-46
158
Lopalco P L, Johansen K, Ciancio B, De Carvalho Gomes H, Kramarz P, Giesecke J.
Monitoring and assessing vaccine safety: a European perspective.
Expert Rev Vaccines.
2010;
9
(4)
371-380
James J SejvarM.D.
Neuroepidemiologist, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
1600 Clifton Road, Mailstop A-39, Atlanta, GA 30333
Email: zea3@cdc.gov